论文部分内容阅读
多发性骨髓瘤治疗中,口服用药相对于静脉用药有许多优点,近年来大量临床试验及免疫调节剂和新型生物靶向药物的出现给多发性骨髓瘤的治疗带来新的思路,本文阐述其应用机制及研究进展。
In the treatment of multiple myeloma, oral administration has many advantages over intravenous administration. In recent years, a large number of clinical trials and the emergence of new immunomodulatory agents and new bio-targeted drugs have brought new ideas to the treatment of multiple myeloma. Application Mechanism and Research Progress.